Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Regular Article
Possible Involvement of β1-Adrenoceptors in the Positive Chronotropic Effects of Mirabegron
Kazuo Noguchi Aino NagaiNana KashimotoRikako KobayashiKazuha OkawaMina ShinkumaRina InoueHaruna KanaeMidori MatsushitaChinami Ueda
著者情報
ジャーナル オープンアクセス HTML

2026 年 49 巻 1 号 p. 47-56

詳細
抄録

Mirabegron, a β3-adrenoceptor agonist used to treat overactive bladder, is associated with increased heart rate; however, the mechanism underlying its cardiac effect remains unclear. In this study, we investigated the β-adrenoceptor subtypes that are involved in the chronotropic effects of mirabegron in mouse and guinea pig atria. Mirabegron (0.03–10 μM) produced concentration-dependent positive chronotropic effects in both species, with maximum effects of 75.9% in mice and 27.7% in guinea pigs. Isoproterenol (0.1–100 nM), a nonselective β-adrenoceptor agonist, dobutamine (0.001–100 μM), a β1-adrenoceptor agonist, and salbutamol (0.001–100 μM), a β2-adrenoceptor agonist, induced concentration-dependent positive chronotropic effects, with the potency order of isoproterenol > dobutamine > mirabegron ≥ salbutamol in mice, and isoproterenol > dobutamine ≥ salbutamol > mirabegron in guinea pigs. Mirabegron-induced positive chronotropic effects were unaffected by 0.1% dimethyl sulfoxide in the mouse atria, but non-competitively antagonized by the selective β3-adrenoceptor antagonist L748337 (100–1000 nM), with the slope of the Schild plot being 0.65. The selective β2-adrenoceptor antagonist ICI118551 (30 nM) attenuated the positive chronotropic effects of mirabegron, producing a 3-fold rightward shift in the concentration–response curve. Conversely, the selective β1-adrenoceptor antagonist CGP20172A (0.03–3 nM) strongly and non-competitively antagonized mirabegron-induced positive chronotropic effects in mouse and guinea pig atria. These results suggest that the positive chronotropic effects of mirabegron are primarily mediated through β1-adrenoceptors, with minimal or no involvement of β2- and β3-adrenoceptors.

Fullsize Image
著者関連情報
© 2026 The Author(s).
Published by The Pharmaceutical Society of Japan

This article is licensed under a Creative Commons [Attribution-NonCommercial 4.0 International] license.
https://creativecommons.org/licenses/by-nc/4.0/
前の記事 次の記事
feedback
Top